生物制药公司aTyr Pharma（ATYR）周一盘中股价大幅下挫81.84%，创下历史性跌幅。这一暴跌主要源于公司核心产品研发的重大挫折。
根据aTyr Pharma最新公布的临床试验结果，其用于治疗肺肉瘤病的实验性药物efzofitimod在后期临床试验中未能达到主要目标。这项为期48周、涉及268名患者的研究旨在证明efzofitimod能够比安慰剂更有效地减少患者每日类固醇使用量。然而，结果显示接受高剂量efzofitimod治疗的患者组与安慰剂组在类固醇用量减少方面并无统计学上的显著差异。
这一结果无疑是对aTyr Pharma的沉重打击。肺肉瘤病是一种影响肺部和淋巴结的炎症性疾病，目前的标准治疗方案主要依赖类固醇。aTyr Pharma此次研发失利，不仅打破了市场对公司开发新型治疗方案的期待，也可能影响公司未来的发展方向。尽管公司表示将与美国食品药品监督管理局（FDA）讨论该药物的后续计划，但投资者对公司前景的信心已经受到严重打击，导致股价出现如此剧烈的跌幅。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.